Abstract Number: VPB1007
Meeting: ISTH 2022 Congress
Background: Trauma and surgery are often associated with large blood loss. Particular life threat circumstances are those that occur against the background of taking antithrombotic drugs. Clinical practice has a range of hemostatic drugs that are widely used to limit blood loss. However, there is a risk of thrombosis with their use. The search for effective and safe drugs with a systemic hemostatic effect remains relevant.
Aims: To present data on the presence of systemic hemostatic activity of exogenous fibrin monomer of human origin in dosed trauma in animals in the experiment against the background of antithrombotic and fibrinolytic therapy.
Methods: Studies were performed in accordance with Directive 86/609/EEC and the Declaration of Helsinki. Suppression of the hemostasis system activity was carried out by heparin, warfarin, dabigatran, clopidogrel in combination with aspirin and streptokinase. We analyzed the reduction of local blood loss against the background of intravenous administration of exogenous fibrin monomer (FM 0.25 mg/kg) after a dosed liver injury in comparison with the use of protamine sulfate (with heparin therapy), prothrombin complex concentrate (with warfarin therapy), Eptacog alfa (with dabigatran etexilate), tranexamic acid (dual antiplatelet therapy). The wound surface in the area of liver injury was examined histologically, including staining for fibrin. The data were evaluated using the MedCalc Version 17.9.7 program.
Results: The ability of the applied dose of FM to decrease wound bleeding (by 2.9–11.0 times) was shown depending on the type of pharmacological effect. The systemic administration of FM did not affect the analyzed parameters of the hemostasis system, in contrast to the prothrombogenic effects of known drugs with systemic hemostatic effects. The selective formation of fibrin in the area of injury was demonstrated when using exogenous FM.
Conclusion(s): The hemostatic properties of FM can be considered as an alternative in the development of new drugs with a systemic hemostatic effect.
To cite this abstract in AMA style:Vdovin V, Shakhmatov I, Momot A. Overview of Hemostatic Effects of Exogenous Fibrin Monomer with Systemic Use in the Experiment [abstract]. https://abstracts.isth.org/abstract/overview-of-hemostatic-effects-of-exogenous-fibrin-monomer-with-systemic-use-in-the-experiment/. Accessed September 27, 2022.
« Back to ISTH 2022 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/overview-of-hemostatic-effects-of-exogenous-fibrin-monomer-with-systemic-use-in-the-experiment/